Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss

Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss at other companies

Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
——

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss?
BioCryst Pharmaceuticals (BCRX) reported debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss of $86.7M in Q1 2026.
How has BioCryst Pharmaceuticals's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss changed year-over-year?
BioCryst Pharmaceuticals's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss decreased by 58.6% year-over-year, from $209.2M to $86.7M.
What is the long-term trend for BioCryst Pharmaceuticals's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss?
Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss has grown at a 20.9% compound annual growth rate (CAGR), from $138.2M to $244.46M.